EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Li Li, Yihan Xu, Yuchao Wang, Qian Zhang, Yan Wang, Chunhua Xu iD

Technology in Cancer Research & Treatment · 2024

DOI: 10.1177/15330338241265983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Li Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Affiliated to Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Keratin-19, Carcinoembryonic Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Medical Scientific Research Project of Jiangsu Provincial Commission Health and Family Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Finding biomarkers related to non-small cell lung cancer (NSCLC) is helpful for the diagnosis and precise treatment of lung cancer. The relationship between serum tumor M2-pyruvate kinase (TuM2-PK), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) and NSCLC was analyzed.

Methods

The serum levels of TuM2-PK, CEA, and CYFRA21-1 in 184 patients with the NSCLC group, 60 patients with the benign lung disease (BLD) group, and 90 healthy controls (HC) group were detected. The levels of TuM2-PK were measured by using an enzyme-linked immunosorbent assay. The detection methods of CEA and CYFRA21-1 were electrochemiluminescence. The receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of TuM2-PK, CEA, and CYFRA21-1 on NSCLC. The Kaplan–Meier survival curve was drawn to evaluate the survival status in NSCLC patients with different serum levels of TuM2-PK, CEA, and CYFRA21-1.

Results

Serum levels of TuM2-PK, CEA, and CYFRA21-1 in the NSCLC group were significantly higher than those in the BLD group and the HC group ( P < .01). Serum levels of TuM2-PK, CEA, and CYFRA21-1 in NSCLC patients were associated with the tumor lymph node metastasis stage ( P < .05), lymph node metastasis ( P < .05), and distant metastasis ( P < .05). The ROC curve showed that the area under the curve of serum levels of TuM2-PK, CEA, and CYFRA21-1 was 0.814, 0.638, and 0.719, respectively, and that the combination of the above 3 was 0.918. The Kaplan–Meier survival curve showed that the 1-, 3- and 5-year survival rate in NSCLC patients with positive TuM2-PK, CEA, and CYFRA21-1 was significantly lower than that in NSCLC patients with negative TuM2-PK, CEA, and CYFRA21-1, respectively ( P < .05).

Conclusions

Serum TuM2-PK, CEA, and CYFRA21-1 levels have high clinical values in the diagnosis of NSCLC, and can effectively judge the prognosis of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungKeratin-19Carcinoembryonic AntigenBiomarkers, TumorROC CurveLung NeoplasmsAntigens, NeoplasmPyruvate KinaseHumansFemaleMalePrognosisMiddle AgedAgedAdultNeoplasm StagingKaplan-Meier EstimateCase-Control Studies

Stichwörter der Autor:innen

carcinoembryonic antigencytokeratin 19 fragmentdiagnosisnon-small cell lung cancerprognosistumor M2-pyruvate kinase

Substanzen

Keratin-19Carcinoembryonic AntigenBiomarkers, Tumorantigen CYFRA21.1Antigens, NeoplasmPyruvate Kinase

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Affiliated to Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Respiratory Medicine, Affiliated to Nanjing Chest Hospital, Southeast University, Nanjing, Jiangsu, China.
  • Nanjing Ninghai High School, Nanjing, Jiangsu, China.
  • Medical Imaging Department II, Affiliated to Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Chunhua Xu

Förderung

  • the Medical Scientific Research Project of Jiangsu Provincial Commission Health and Family Planning

Zitieren

APA

Li, L., Xu, Y., Wang, Y., Zhang, Q., Wang, Y., & Xu, C. (2024). The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241265983

Vancouver

Li L, Xu Y, Wang Y, Zhang Q, Wang Y, Xu C. The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241265983

BibTeX
@article{Li2024,
  author = {Li, Li and Xu, Yihan and Wang, Yuchao and Zhang, Qian and Wang, Yan and Xu, Chunhua},
  title = {The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  doi = {10.1177/15330338241265983}
}
Kostenlos starten →